Cancer tissue sample handled by the Integrated BioBank of Luxembourg
Photo: Integrated BioBank of Luxembourg
Science: The Grand Duchy’s biobank has started investigating how US cancer samples are prepared for research labs.
A Luxembourg biomedical outfit has started working with America’s premiere cancer research institute on improving cancer research methods. On Tuesday the Integrated BioBank of Luxembourg said it began analysing cancer tissues collected by the US National Cancer Institute.
The aim is to “investigate procedural variations” in how samples are handled before they are examined by researchers, and potentially create “quality control tools for tissue biospecimens”.
“Though traditional biobanking activities such as sample collection, processing and storage are the bread and butter of our foundation, internal biospecimen science research is a key component in achieving our missions”, Catherine Larue, IBBL’s CEO, said in a press announcement.
Four year old IBBL collects and analysis biological samples and data, which are then used by health research organisations in the Grand Duchy, Belgium, Canada, France, Germany, Israel, Sweden, Switzerland, the UK and US. In addition to cancer, it focuses on other diseases such as diabetes and Parkinson’s. The not-for-profit institute had a budget of €8 million last year.
The NCI was founded by the US government in 1937 and in 2012 funded more than $5 billion in research. A 1996 report found that NCI supported the development of two-thirds of anti-cancer drugs approved in America.